Last reviewed · How we verify
XTR004
XTR004 is a small molecule targeting the SGLT2 receptor.
XTR004 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | XTR004 |
|---|---|
| Also known as | Drug: 99mTechnicium Sestamibi, Procedure: Coronary angiography |
| Sponsor | Sinotau Pharmaceutical Group |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, XTR004 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) (PHASE3)
- Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis (PHASE2)
- Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD (PHASE2)
- A Study of XTR004 Radiotracer in Healthy Volunteers (PHASE1)
- 18F-FMPP PET MPI in the Detection of Coronary Artery Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XTR004 CI brief — competitive landscape report
- XTR004 updates RSS · CI watch RSS
- Sinotau Pharmaceutical Group portfolio CI